Condition
Esophageal Cancer Stage III
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 2 (3)
P 3 (1)
Trial Status
Completed2
Unknown1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06965829Phase 2Not Yet RecruitingPrimary
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
NCT03087864Phase 2Completed
PDL-1 Targeting in Resectable Oesophageal Cancer
NCT03366883Phase 3Unknown
Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC
NCT00578201Phase 2CompletedPrimary
FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer
Showing all 4 trials